Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.

Abstract: The object of the invention is a compound of formula (I), or a stereoisomer or salt thereof, wherein R1 and R2 are selected from the group consisting of N, N+—CH3, N+—C2H5, N+—C3H8, N+—C4H5, N+—CH2C6H5 wherein at least one of R1, R2 is not N. n and m are independently chosen from the group consisting of 0, 1 and 2; X is selected from the group consisting of O, NH, S, CH2 k is 1 or 2 Y is either void or selected from the group of —CH2—, —CH2CH2—, —CH2O—, —CH2S—, —CH2NH—, —CH2CH2O—, —CH2CH2NH—, —CH2CH2S— R3, R4, R5, R6 are selected from the group consisting of H, OH, OCH3, or OCH2CH3; wherein R3 and R4 may be the same or different; R5 and R6 may be the same or different; if either of R3, R4 is different than OH than R5 and R6 are both OH; if either of R5, R6 is different than OH than R3 and R4 are both OH.

Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

Abstract: A method is disclosed that exploits the combined features of carbohydrate binding modules (CBM) and nanocrystalline cellulose (CNC) for ‘fishing out’ specific agents of interest (AOI), such as proteins, which are optionally present or produced in culture.

Abstract: The invention relates to a chromatography system and method for assessing amount and/or purity of a multimeric protein in a sample, wherein the chromatography system comprises two different affinity chromatography matrices connected via a switch valve.

Abstract: The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below: wherein the definitions of T, Q, R1 and R2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.

Abstract: Fluorescence resonance energy transfer (FRET) constructs comprising donor and acceptor fluorophore moieties, and a peptide linking the two, which is a substrate of the endopeptidase fibroblast activation protein (FAP). Also provided are isolated nucleic acids expressing the construct, cell lines comprising the nucleic acids, and kits comprising the construct. Further provided are methods of detecting FAP using the construct via FRET.

Abstract: Peptoids are described herein, as well as compositions comprising an aqueous liquid and a peptoid soluble in the aqueous liquid. The peptoids comprise a plurality of N-substituted glycine residues and/or N-substituted ?-alanine residues, and at least one heteroalicyclic residue having a general formula: wherein W, X, Y1, Y2, Z1 and Z2 are as defined herein.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: Embodiments of the present invention relate to inteins, split inteins, compositions comprising inteins and methods for use of these.

Abstract: The invention features immunogenic compositions and vaccines containing an optimized human immunodeficiency virus (HIV) envelope (Env) polypeptide (e.g., a stabilized trimer of optimized HIV Env polypeptides) or a polynucleotide encoding an optimized HIV Env polypeptide and uses thereof. The invention also features methods of treating and/or preventing a HIV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).

Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (deposition number KCTC 12854BP), a pharmaceutical composition including the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium by using the pharmaceutical composition, the antibacterial protein EFAL-2 being characterized by having the ability capable of killing Enterococcus faecium and having an amino acid sequence represented by SEQ ID NO: 2.

Abstract: Methods and systems for designing, testing, and validating genome designs are described herein. A computer-implemented method includes receiving data for a known genome and a list of alleles, identifying and removing occurrences of each allele in the known genome, determining a plurality of allele choices with which to replace occurrences in the known genome, generating a plurality of alternative gene sequences for a genome design based on the known genome, applying a plurality of rules or constraints or conditions or parameters or features to each alternative gene sequence by assigning a score for each rule or constraint or condition or parameter or feature in each alternative gene sequence, resulting in scores, scoring each alternative gene sequence based on a weighted combination of the scores, and selecting at least one alternative gene sequence as the genome design based on the scoring.

Abstract: In a first aspect, the present invention relates to a mutated Salmonella strain comprising mutations in flagellin II genes, like the fliF gene, in particular, in addition the aroA gene, the IpxR gene, the pagP gene, the pagL gene, the ydiV gene and optionally the eptA gene and further optionally, the arnT gene. In a further aspect, immunogenic compositions comprising said Salmonella strain are provided optionally together with a pharmaceutically accepted carrier, diluent or effluent. Moreover, a method for producing outer membrane vesicles of Salmonella is provided, said method comprises the steps of cultivating the Salmonella strain according to the present invention and isolating the outer membrane vesicles accordingly.

Abstract: Methods are described herein for generating beneficial compounds and/or materials such as bacteriocins that include contacting ‘challenger’ microbes with the ‘protagonist’ microorganisms. The challenger microbes do not directly manufacture the beneficial compounds and/or materials and instead stimulate the protagonist microorganisms to produce beneficial compounds and materials. The protagonist and/or challenger microorganisms can be administered to a subject so the beneficial compounds and/or materials can be made in vivo. Compositions and methods of using beneficial compounds and/or materials are also described herein.

Abstract: Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity.

Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:61-121 and 133-141, or the nucleotide sequence set forth in SEQ ID NO:1-60, 124-132, and 142-283, as well as variants and fragments thereof.

Abstract: A transgenic land plant is provided. The transgenic land plant comprises a mitochondrial transporter protein of a eukaryotic algae. The mitochondrial transporter protein of the eukaryotic algae is heterologous with respect to the transgenic land plant. The mitochondrial transporter protein is a sequence or ortholog of CCP1 of Chlamydomonasreinhardtii, a mitochondrial transporter protein of Chlorella sorokiniana, a mitochondrial transporter protein of Chlorella variabilis, a mitochondrial transporter protein of Chondrus crispus, a mitochondrial transporter protein of Gonium pectorale, or a mitochondrial transporter protein of Volvox carteri. The mitochondrial transporter protein is localized to mitochondria of the transgenic land plant based on a mitochondrial targeting signal intrinsic to the mitochondrial transporter protein.

Abstract: The invention provides chimeric antigen receptor(s) (CAR(s)) that comprise a fusion protein of CTX or any functional variant thereof or a CTX-like peptide or any functional variant thereof as the extracellular antigen recognition moiety of the CAR. CAR(s) comprising CTX, a CTX-like peptide or functional variants of the foregoing are collectively referred to herein as “CTX-CAR(s).” Such CTX-CAR(s) may further comprise additional moieties or domains in the extracellular domain, a transmembrane domain and at least one intracellular! signaling domain. Such CTX-CAR(s) may be expressed in a host cell, such as, but not limited to, an immune effector cell. The present invention also provides methods of treatment (such as, for example, methods for treating cancer) by providing to the patient in need thereof immune effector cells that are engineered to express a CTX-CAR described herein.

Abstract: The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an ?-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a ??o core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.

Abstract: The disclosure provides interleukin 37 (IL-37) fusion proteins, methods of making IL-37 fusion proteins including constructs used to express IL-37 fusion proteins, and methods of using IL-37 fusion proteins. In some embodiments, the IL-37 fusion protein includes amino acids 46-206 of isoform B of IL-37 and a heavy chain portion of an antibody.

Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.

Abstract: Compositions and methods for treating, mitigating, or preventing a Toll-like receptor (4) (TLR4)-mediated infection or disease in a host cell or a subject include administration of a resistin protein composition selected from full length resistin protein, a resistin protein fragment, or a fusion protein of resistin and an immunoglobulin G protein to the host cell or the subject having or likely to be exposed to a TLR4-mediated infection or disease.

Abstract: An insulin analogue comprises an insulin B-chain polypeptide containing a Trp substitution at position B26 relative to the sequence of wild-type insulin. The insulin analogue may additionally comprise an OrnB29 substitution, a C-terminal extension of one or two basic amino acids such as Arg-Arg, a GlnB13 substitution, a GlyA21 substitution, a HisA8 or ArgA8 substitution, or a combination thereof. The insulin analogue may be formulated in the presence of zinc ions at a molar ratio of 2.2-10 zinc ions per six insulin analogue monomers. The molecular design is believed to stabilize the dimer interface of insulin (and its stable formulation as a zinc insulin hexamer) by means of aromatic amino-acid substitutions at position B26 of the B chain. The insulin analogs of the present invention may have two chains (A and B) as in mammalian insulins or may be engineered with a C domain (4-12 amino acids in length) to provide a single-chain.

Abstract: Provide is an artificially synthesized antitumor peptide that may suppress proliferation of tumor cells. The peptide provided is a synthetic peptide that contains both (1) an amino acid sequence that forms a signal peptide of a membrane protein, programmed cell death-1 (PD-1), or a modified amino acid sequence thereof in which 1, 2 or 3 amino acid residues deleted from, substituted in or added to the above amino acid sequence; and (2) an amino acid sequence that serves as a cell penetrating peptide (CPP), and wherein the synthetic peptide comprises a total of 100 or fewer amino acid residues.

Abstract: Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

Abstract: The present disclosure relates to chimeric engulfment receptor molecules, host cells modified to include the phagocytic engulfment molecules, and methods of making and using such receptor molecules and modified cells.

Abstract: Minor histocompatibility antigens (MiHAs) binding to certain human leukocyte antigen (HLA) alleles are described. These MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these MiHAs are also described. The present application also discloses the use of these MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

Abstract: In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer.

Abstract: The invention encompasses the discovery that Fc-containing polypeptides that include branched glycans and that are sialylated on the branched glycan (e.g., on an ? 1,3 and/or ? 1,6 arm in the Fc region's N-linked glycosylation site), with, e.g., a NeuA-? 2,6-Gal or NeuAc-? 2,3-Gal terminal linkage, are useful in treating neurodegeneration, e.g., in the treatment of neurodegenerative diseases such as Alzheimer's Disease. The present disclosure provides, in pert, methods for treating neurodegeneration or neurodegenerative diseases by administering compositions containing such Fc-containing polypeptides as well as methods for evaluating, identifying, and/or producing (e.g., manufacturing) such polypeptides for the treatment of neurodegeneration.

Abstract: The present invention relates to immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy using immunoglobulin products. In particular, the present invention provides efficacious dosing regimens.

Abstract: The present invention relates to the field of biotechnology, and in particular to the field of antibodies. Provided herein are novel methods for removing glycosylated antibody variants from an antibody preparation, an antibody preparation obtained by said method, and a pharmaceutical composition comprising the same.

Abstract: Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.

Abstract: The present invention relates to a method for preparing a whole bovine-derived broadly neutralizing antibody against serotype O foot-and-mouth disease virus, and belongs to the technical field of antibody preparation.

Abstract: The present invention relates to methods for treating hypercytokinemia and viral infections associated with hypercytokinemia using a mast cell stabilizing compound, optionally in combination with an antiviral agent. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents, optionally with an antiviral agent.

Abstract: The present invention relates to methods for treating hypercytokinemia and viral infections associated with hypercytokinemia using a mast cell stabilizing compound, optionally in combination with an antiviral agent. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents, optionally with an antiviral agent.

Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.

Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.

Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.

Abstract: The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Abstract: Disclose herein are dosing regimens for targeted NaPi2b antibody-drug conjugates for treating cancer.

Abstract: A therapeutic agent comprising a cell binding agent which binds the Receptor for Advanced Glycation Endproducts (RAGE) linked to an anti-cancer drug, for use in the treatment of gynaecological cancer, endometriosis or polycystic ovary syndrome. Novel cell binding agents, pharmaceutical compositions and methods are also described.

Abstract: Anti-TIM-3 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.

Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Abstract: This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting CTLA-4 expressed on injured tissues associated with multiple diseases. These anti-CTLA-4 antibodies, or antigen-binding fragments thereof, have a high affinity for CTLA-4 and function to inhibit CTLA-4. The antibodies and antigen-binding fragments are useful for treatment of human diseases, infections, and other conditions.

Abstract: The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.

Abstract: The invention provides anti-MIC antibodies and methods of using the same.